Acumen Pharmaceuticals (ABOS) News Today → The World's First '$20 Trillion Drug?' (From Behind the Markets) (Ad) Free ABOS Stock Alerts $3.19 +0.01 (+0.31%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineThese 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analystsmarkets.businessinsider.com - April 18 at 7:21 PMAcumen Pharmaceuticals (ABOS) Price Target Increased by 6.67% to 13.06msn.com - April 17 at 2:50 PMAcumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 16 at 8:00 AMAcumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s Treatmentfinance.yahoo.com - April 4 at 7:02 PMAcumen Pharma Partners Lonza To Advance Sabirnetug For Alzheimer's Disease Treatmentmarkets.businessinsider.com - April 4 at 9:02 AMAcumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Diseasefinance.yahoo.com - April 4 at 9:02 AMAcumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Diseaseglobenewswire.com - April 4 at 8:00 AMSames Auto Group partners with Driscoll Children’s Hospitalmsn.com - April 4 at 4:01 AMAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) to Post Q2 2024 Earnings of ($0.26) Per Share, HC Wainwright Forecastsmarketbeat.com - March 29 at 8:36 AMAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Forecasted to Post Q1 2024 Earnings of ($0.26) Per Sharemarketbeat.com - March 28 at 8:24 AMAcumen Pharmaceuticals files for $200M mixed shelf offeringmsn.com - March 27 at 9:00 PMBuy Rating Affirmed for Acumen Pharmaceuticals on Promising Alzheimer’s Drug Trial Outcomesmarkets.businessinsider.com - March 27 at 3:59 PMBuy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Alzheimer’s Treatment Development and Attractive Valuationmarkets.businessinsider.com - March 27 at 3:59 PMQ4 2023 Acumen Pharmaceuticals Inc Earnings Callfinance.yahoo.com - March 27 at 10:58 AMAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 27 at 10:58 AMAcumen Pharmaceuticals (NASDAQ:ABOS) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - March 27 at 10:15 AMAcumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlightsglobenewswire.com - March 26 at 7:00 AMAcumen Pharmaceuticals (ABOS) Scheduled to Post Quarterly Earnings on Tuesdaymarketbeat.com - March 20 at 3:04 PMAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024globenewswire.com - March 19 at 4:00 PMAcumen Pharmaceuticals to Participate in the Stifel 2024 CNS Daysglobenewswire.com - March 12 at 4:00 PMAcumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meetingfinance.yahoo.com - March 8 at 11:04 AMSchonfeld Strategic Advisors LLC Takes $2.68 Million Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)marketbeat.com - March 7 at 6:40 AMInstitutional investors own a significant stake of 42% in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)finance.yahoo.com - February 24 at 9:24 AMAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meetingfinance.yahoo.com - February 21 at 12:31 PMAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meetingglobenewswire.com - February 21 at 8:00 AMABOS Mar 2024 2.500 putfinance.yahoo.com - February 17 at 1:28 AMBuy Alert: 3 Healthcare Stocks Sitting in the Sweet Spotfinance.yahoo.com - February 7 at 3:51 AM3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boomfinance.yahoo.com - February 1 at 8:58 AMAcumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officerfinance.yahoo.com - February 1 at 8:58 AMAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells $10,567.09 in Stockmarketbeat.com - January 19 at 9:19 PMBTIG Reaffirms Their Buy Rating on Acumen Pharmaceuticals (ABOS)markets.businessinsider.com - January 8 at 8:38 AMAcumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 4 at 6:15 PMDeutsche Bank Initiates Coverage of Acumen Pharmaceuticals (ABOS) with Buy Recommendationmsn.com - December 13 at 7:37 AMAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 14 at 1:23 PMQ3 2023 Acumen Pharmaceuticals Inc Earnings Callfinance.yahoo.com - November 14 at 1:18 AMAcumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 13 at 3:17 PMAcumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlightsmarkets.businessinsider.com - November 13 at 10:16 AMAcumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVenturesmarkets.businessinsider.com - November 13 at 10:16 AMAcumen Pharmaceuticals's Earnings Outlookbenzinga.com - November 10 at 6:01 PMHalozyme, Acumen enter collaboration for Alzheimer's drug candidatemsn.com - November 7 at 1:00 PMQ3 2023 Halozyme Therapeutics Inc Earnings Callfinance.yahoo.com - November 7 at 1:00 PMAcumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023finance.yahoo.com - November 6 at 8:38 PMAcumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technologyfinance.yahoo.com - November 6 at 10:37 AMAcumen Pharmaceuticals to Participate in the UBS Biopharma Conferencefinance.yahoo.com - November 2 at 5:30 PMAcumen’ presents new data on its ACU193 in Phase I trial for ADmsn.com - October 31 at 1:08 AMAnalysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and Alector (ALEC)markets.businessinsider.com - October 30 at 10:06 AMAcumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Diseasefinance.yahoo.com - October 27 at 1:14 PMAcumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)finance.yahoo.com - October 4 at 8:08 AMNavigating Acumen's Alzheimer's Risk And Rewardmsn.com - October 3 at 2:48 PMAcumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conferencefinance.yahoo.com - September 19 at 8:02 PM Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address The World's First "$20 Trillion Drug?" (Ad)One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%! Get the name of the stock here >>> ABOS Media Mentions By Week ABOS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABOS News Sentiment▼1.050.37▲Average Medical News Sentiment ABOS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABOS Articles This Week▼12▲ABOS Articles Average Week Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IPHA News Today ELEV News Today OPT News Today CRDF News Today CMPX News Today KOD News Today IPSC News Today XFOR News Today OVID News Today PSTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABOS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
